<DOC>
	<DOCNO>NCT02097459</DOCNO>
	<brief_summary>It suggest Guideline postmenopausal woman breast cancer take selective estrogen receptor modulators ( SERMs ) therapy 2-3 year could benefit change endocrine therapy aromatase inhibitor ( AIs ) . This prospective , randomized non-inferior trial evaluate prognosis change endocrine therapy SERMs AIs perimenopausal recently postmenopausal woman early-stage hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>Prognostic Evaluation Changing Endocrine Therapy Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Written informed consent must obtain document accord local regulatory requirement prior begin specific protocol procedure . Age least 45 55 year . Performance status ( KarnofskyIndex ) ï¼ž80 % Steroid receptor ( estrogen progesterone ) positive tumor ( diagnosis accord hospital standardprocedures ) . No clinical evidence local recurrence distant metastasis . Complete stag workup within 3 month prior registration . All patient must ( bilateral ) mammography breast MRI , chest Xray ; test may perform clinically indicate . Patients take SERMs endocrine therapy 24 year . Patients amenorrhea least half year . Life expectancy least 10 year , disregard diagnosis cancer . Adequate organ function include normal red white blood count , platelet , serum creatinine , bilirubin , transaminase within normal range institution . Patients must available compliant treatment followup . Patients register trial must treat follow participate center . Known hypersensitivity reaction investigational compound incorporated substance . Hormone receptornegative breast cancer . Local recurrence and/or metastasis breast cancer . History hysterectomy . Pregnant lactating patient . Patients childbearing potential must negative pregnancy test ( urine serum ) within 14 day prior registration . History osteoporosis and/or fracture due osteoporosis . Prior concomitant secondary malignancy ( except nonmelanomatous skin cancer carcinoma situ uterine cervix ) Any serious medical pathology , congestive heart failure ; unstable angina ; history myocardial infarction previous year ; uncontrolled high risk arrhythmia Other serious illness medical condition may interfere understand give informed consent conduct study . Concurrent treatment experimental drug anticancer therapy . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Endocrine therapy</keyword>
	<keyword>Perimenopausal recently postmenopausal patient</keyword>
	<keyword>Early-stage hormone receptor-positive</keyword>
</DOC>